Project Grant DP1DA066476
Award Date 9/15/26
Completion Date 7/31/31
Dollars Obligated $468K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Wisconsin–Madison $209,496 in a Cooperative Agreement (UG3DA061658) on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds development and implementation of novel in vivo methods to study mu-opioid receptor actions in the prefrontal cortex, specifically intra-cortical peptide release and activity profiles of mu-opioid-receptor-expressing projection neurons in the infralimbic cortex. The...
- The National Institute on Drug Abuse awarded Wake Forest University Health Sciences $556,484 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct cell-type-specific proteomic analysis of microglial protein dynamics in models of HIV and opioid use disorder comorbidity. The project employs a state-of-the-art proteomic strategy using a Cre-dependent mutant methionyl-tRNA synthetase system to label nascent proteins in microglia in vivo with the noncanonical...
- The National Institute on Drug Abuse awarded the University of Washington $100,228 on November 10, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize the role of endogenous nociceptin opioid release from the central amygdala in reward outcome encoding. The recipient will conduct research examining how nociceptin-containing neurons in the central amygdala engage distinct reward properties—including reward probability and size—and project to the lateral...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $661,299 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into opioid use disorder mechanisms and potential therapeutic targets. The research, titled "A Novel Cellular and Circuit Target for Opioids," investigates a transcriptionally distinct neuronal population in the nucleus accumbens that expresses high levels of the mu opioid receptor...
- The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement of $733,457 to The Washington University on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research investigating the long-term neurodevelopmental impact of maternal opioid exposure and opioid management strategies in rodent offspring. The project evaluates how in utero oxycodone exposure, maintenance therapy with methadone and buprenorphine, and withdrawal mitigation...
- The National Institute on Drug Abuse awarded the Regents of the University of Michigan $595,171 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate functional anatomy, physiology, and behavioral responses mediated by mu opioid receptor signaling on medial thalamic neurons. The research addresses opioid withdrawal-induced hyperalgesia (OWIH)—exaggerated pain perception that occurs when opioid-dependent individuals discontinue use. The project uses...
- The National Institute on Drug Abuse awarded The University of Texas Health Science Center At San Antonio $163,350 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the molecular regulation of the kappa opioid receptor by 14-3-3 gamma. The research examines mechanisms underlying long-term inhibition of opioid receptor signaling in peripheral neurons, with the goal of developing safer, non-addictive pain treatments that target the peripheral...
- The National Institute on Drug Abuse awarded The Regents of the University of California, San Francisco $200,880 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the spatiotemporal dynamics of G protein signaling by opioid receptors. The research investigates how mu-opioid receptors trigger cellular signaling pathways across multiple subcellular compartments, particularly endosomes, to advance understanding of opioid function relevant to...